Clinical trial • Phase IV • Other
DEXMEDETOMIDINE for Thoracoscopic lung resection surgery
Phase IV trial of DEXMEDETOMIDINE for Thoracoscopic lung resection surgery.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Thoracoscopic lung resection surgery
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 09-01-2024
- First CTIS Authorization Date
- 02-04-2024
Trial design
Sodium Chloride 0.9% Intravenous Infusion (placebo); max total amount listed: 100 ml; route: intravenous infusion.-controlled Phase IV trial across 1 site in Belgium.
- Comparator
- Sodium Chloride 0.9% Intravenous Infusion (placebo); max total amount listed: 100 ml; route: intravenous infusion.
- Target Sample Size
- 102
Eligibility
Recruits 102 Participants are adults aged 60 years or older; vulnerable population not selected. Exclusion criterion: "Lack of informed consent or inability to give informed consent" (informed consent required from participant)..
- Vulnerable Population
- Participants are adults aged 60 years or older; vulnerable population not selected. Exclusion criterion: "Lack of informed consent or inability to give informed consent" (informed consent required from participant).
Inclusion criteria
- {"criterion_text":"- Adult patients aged 60 years or older"}
- {"criterion_text":"- Patients scheduled for thoracoscopic lung resection surgery"}
Exclusion criteria
- {"criterion_text":"- Lack of informed consent or inability to give informed consent"}
- {"criterion_text":"- 2nd- or higher degree atrioventricular block without pacemaker"}
- {"criterion_text":"- urgent, not elective surgery"}
Endpoints
Primary endpoints
- {"endpoint_text":"- (Early) quality of recovery on day 1 following surgery compared to preoperative value, assessed by the quality of recovery score (QoR-15).","definition_or_measurement_approach":"Assessed by the quality of recovery score (QoR-15) comparing day 1 post-surgery to preoperative value."}
Secondary endpoints
- {"endpoint_text":"- The Quality of Recovery Score (QoR-15) will be used to assess the early postoperative health status of the patient, i.e. the quality of recovery","definition_or_measurement_approach":"Measured using the QoR-15 questionnaire to assess early postoperative health status/quality of recovery."}
- {"endpoint_text":"- Postoperative muscle strength (lower extremity) and physical ability, assessed by the Timed Up and Go test (TUG)","definition_or_measurement_approach":"Measured by the Timed Up and Go test (TUG) to assess lower extremity strength and physical ability."}
- {"endpoint_text":"- Postoperative muscle function and decrease in strength (upper extremity) postoperatively will be assessed by comparing the handgrip strength of the dominant hand, measured by the CAMRY dynamometer","definition_or_measurement_approach":"Measured by handgrip strength of the dominant hand using a CAMRY dynamometer; comparison pre/postoperative."}
- {"endpoint_text":"- To assess general fatigue a fatigue questionnaire, the Chalder fatigue questionnaire, will be taken","definition_or_measurement_approach":"Measured using the Chalder fatigue questionnaire."}
- {"endpoint_text":"- To assess fatigue more in detail the fatigue VAS scale will be taken","definition_or_measurement_approach":"Measured using a fatigue visual analogue scale (VAS)."}
- {"endpoint_text":"- The EQ-5D questionnaire will be taken to assess health-related quality of life","definition_or_measurement_approach":"Measured using the EQ-5D questionnaire to assess health-related quality of life."}
- {"endpoint_text":"- Electroencephalographic (EEG) readings will be conducted (in a subcohort of patients) during the first postoperative night (when administering study medication) via a compact/wearable medical device for recording brain activity","definition_or_measurement_approach":"EEG recordings via a compact/wearable device during the first postoperative night in a subcohort."}
- {"endpoint_text":"- To evaluate each patient’s sleep-wake cycle, the sleep-wake timing will be evaluated with the Munich ChronoType Questionnaire (MCTQ), which will be used to calculate the baseline midpoint sleep and chronotype","definition_or_measurement_approach":"Assessed via the Munich ChronoType Questionnaire (MCTQ) to calculate baseline midpoint sleep and chronotype."}
- {"endpoint_text":"- To assess subjective sleep quality the Pittsburgh Sleep Quality Index (PSQI; a seven-item questionnaire consisting of 19 self-rated questions that assess sleep quality over the last month, each weighted equally on a 0-3 scale; higher scores indicate worse sleep quality) will be used","definition_or_measurement_approach":"Measured using the Pittsburgh Sleep Quality Index (PSQI) questionnaire (19 self-rated questions)."}
- {"endpoint_text":"- The evolution of sleep pre- and postoperatively will be evaluated with the Consensus Sleep Diary to have a more depth insight into the evolution of sleep pre- and postoperatively","definition_or_measurement_approach":"Assessed using the Consensus Sleep Diary to evaluate pre- and postoperative sleep evolution."}
- {"endpoint_text":"- The Richards-Campbell Sleep Questionnaire (RCSQ) will be taken to evaluate the subjective quality of the first night after surgery","definition_or_measurement_approach":"Measured using the Richards-Campbell Sleep Questionnaire (RCSQ) for subjective quality of the first postoperative night."}
- {"endpoint_text":"- To assess postoperative delirium the 3 minute confusion assessment method (3D-CAM) questionnaire will be done","definition_or_measurement_approach":"Assessed using the 3D-CAM (3 minute confusion assessment method) questionnaire."}
- {"endpoint_text":"- To assess postoperative cognitive impairment the Telephone Interview for Cognitive Status (TICS-40) will be done","definition_or_measurement_approach":"Assessed using the TICS-40 (Telephone Interview for Cognitive Status) to evaluate cognitive impairment."}
- {"endpoint_text":"- NRS pain scores 0-10","definition_or_measurement_approach":"Measured using Numerical Rating Scale (NRS) for pain from 0 to 10."}
- {"endpoint_text":"- The occurrence of PONV","definition_or_measurement_approach":"Recorded occurrence of postoperative nausea and vomiting (PONV)."}
- {"endpoint_text":"- Markers of the inflammatory surgical response will be determined","definition_or_measurement_approach":"Measured by laboratory assessment of markers of inflammatory surgical response (details not specified)."}
- {"endpoint_text":"- Melatonin production will be monitored","definition_or_measurement_approach":"Melatonin production monitoring (method not specified)."}
Recruitment
- Planned Sample Size
- 102
- Recruitment Window Months
- 24
- Consent Approach
- Informed consent required from participants. Exclusion: "Lack of informed consent or inability to give informed consent." No assent procedures or languages specified.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 102
Belgium
- Earliest CTIS Part Ii Submission Date
- 04-03-2024
- Latest Decision Or Authorization Date
- 02-04-2024
- Processing Time Days
- 29
- Number Of Sites
- 1
- Number Of Participants
- 102
Sites
- Site Name
- Ziekenhuis Oost Limburg
- Department Name
- Critical care department
- Principal Investigator Name
- Steven Thiessen
- Principal Investigator Email
- steven.thiessen@zol.be
- Contact Person Name
- Steven Thiessen
- Contact Person Email
- steven.thiessen@zol.be
- Number Of Participants
- 102
Sponsor
Primary sponsor
- Full Name
- Ziekenhuis Oost Limburg
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Belgium
Investigational products
- Investigational Product Name
- Dexdor 100 micrograms/ml concentrate for solution for infusion
- Active Substance
- DEXMEDETOMIDINE
- Modality
- Small molecule
- Routes Of Administration
- INTRAVENOUS INFUSION
- Route
- Intravenous infusion
- Authorisation Status
- Authorised (marketing authorisation EU/1/11/718/006)
- Maximum Dose
- 10 µg/Kg (max total / max daily amount as listed)
- Investigational Product Name
- Sodium Chloride 0.9% Intravenous Infusion
- Active Substance
- SODIUM CHLORIDE
- Modality
- Small molecule
- Routes Of Administration
- INTRAVENOUS INFUSION
- Route
- Intravenous infusion
- Authorisation Status
- Authorised (marketing authorisation PL 08828/0034)
- Maximum Dose
- 100 ml (max total / max daily amount as listed)
Related trials
Other published trials that may interest you.